Viibryd Withdrawal & Tapering Guide
vilazodone
Boxed Warning
Suicidality risk in children, adolescents, and young adults under 25 during initial treatment.
In short
Viibryd (vilazodone) is an SSRI with a half-life of 25 hours. Unique dual mechanism (SSRI + 5-HT1A partial agonist).
- Class
- SSRI
- Half-life
- 25 hours
- Common doses
- 10mg, 20mg, 40mg
Educational reference only. Dose changes are decided with the prescriber who knows your history.
Overview
Vilazodone is a selective serotonin reuptake inhibitor (SSRI) and partial agonist at the 5-HT1A receptor. It is used for the treatment of major depressive disorder.
10mg, 20mg, 40mg
Tablets: 10mg, 20mg, 40mg
Category C (risk cannot be ruled out)
Mechanism of Action
Combined SSRI activity with 5-HT1A receptor partial agonism, providing dual serotonergic modulation. Blocks SERT while partially activating 5-HT1A autoreceptors.
Taper Notes
Unique dual mechanism (SSRI + 5-HT1A partial agonist). Must be taken with food for adequate absorption. Taper slowly — withdrawal can include GI disturbance and dizziness.
Hyperbolic Tapering Guidance
Reduce gradually over months. Consider 10mg steps initially, then smaller reductions at lower doses. No liquid formulation available — tablet splitting may be necessary.
Summary written by TaperCommunity, informed by the Maudsley Deprescribing Guidelines (Horowitz & Taylor) and related literature — see Sources & References below. Not affiliated with or endorsed by the Maudsley.
Common Withdrawal Symptoms
Interactions & Safety
Drug Interactions
- MAOIs — contraindicated (risk of serotonin syndrome)
- Strong CYP3A4 inhibitors (ketoconazole) — reduce vilazodone dose to 20mg
- Serotonergic drugs (triptans, tramadol, St. John's Wort) increase serotonin syndrome risk
Food Interactions
- MUST be taken with food — bioavailability drops ~50% without food
- No specific food contraindications beyond the requirement to take with food
Contraindications
- MAOIs within 14 days
- Known hypersensitivity to vilazodone
Toxicity
Serotonin syndrome risk when combined with serotonergic agents. GI side effects are the most common dose-limiting toxicity.
Pharmacokinetics
ADME Profile
Oral bioavailability 72% with food (significantly reduced without food). Tmax ~4–5 hours. Must be taken with food.
Not well characterized; extensively distributed.
Hepatic via CYP3A4 (major), CYP2C19, and CYP2D6. Active metabolites are not clinically significant.
Primarily fecal (2% unchanged in urine).
96–99%
Apparent clearance ~40 L/hr
Need a clinician who understands tapering?
Browse our map of deprescribing-informed providers worldwide.
Other Drug Profiles
The arithmetic of a proportional reduction
The Maudsley Deprescribing Guidelines and NICE NG222 describe reducing SSRI medications by a proportion of the previous dose rather than by a fixed amount, so each cut is smaller than the last. The table shows what that arithmetic produces at 10% per step, using 20 mg only as a worked example. How large each step is, how long it is held, and whether this pattern applies at all are decisions for the person and their prescriber.
| Step | % of starting dose | Worked example (20 mg start) |
|---|---|---|
| Start | 100% | 20 mg |
| Step 1 | 90% | 18 mg |
| Step 2 | 81% | 16.2 mg |
| Step 3 | 73% | 14.6 mg |
| Step 4 | 66% | 13.1 mg |
| Step 5 | 59% | 11.8 mg |
| Step 6 | 53% | 10.6 mg |
| Step 7 | 48% | 9.57 mg |
| Step 8 | 43% | 8.61 mg |
This is an illustration of a published method, not a schedule for anyone. It does not account for how long you have taken Viibryd, your current dose, formulation, or history. TaperCommunity does not recommend doses or dose changes; those are agreed with your prescriber.
Frequently asked questions about Viibryd
What are the withdrawal symptoms of Viibryd (vilazodone)?
Common withdrawal symptoms of Viibryd (vilazodone) include: dizziness, nausea, diarrhea, insomnia, headache, irritability. Symptom severity varies by individual, dose, and duration of use.
How should I taper off Viibryd (vilazodone)?
Unique dual mechanism (SSRI + 5-HT1A partial agonist). Must be taken with food for adequate absorption. Taper slowly — withdrawal can include GI disturbance and dizziness. Reduce gradually over months. Consider 10mg steps initially, then smaller reductions at lower doses. No liquid formulation available — tablet splitting may be necessary.
Can I stop Viibryd cold turkey?
Stopping Viibryd abruptly is not recommended. Its half-life is 25 hours, and the receptor adaptations built up during treatment do not reverse at that speed, so a sudden stop tends to produce the sharpest withdrawal. Prescribing guidance favours gradual, proportional reductions agreed with your prescriber.
How long does Viibryd stay in your system?
Viibryd (vilazodone) has a half-life of 25 hours. A drug is mostly cleared after about five half-lives, so Viibryd is largely out of the body about 5 days after the last dose, longer in older adults or with liver or kidney impairment. Withdrawal symptoms often begin before the drug has fully cleared and continue after it has, because the adaptations the brain made during treatment reverse more slowly than the drug leaves the blood.
Sources & References
Viibryd (vilazodone) information on this page is sourced from peer-reviewed research, regulatory bodies, clinical guidelines, and patient-advocacy organizations.
Encyclopedic & chemical databases
Neutral, high-authority entity references.
Peer-reviewed research
Primary literature cited in this taper guide.
- Horowitz MA, Taylor D 2019 — Tapering of SSRI treatment to mitigate withdrawal symptoms (hyperbolic taper) (The Lancet Psychiatry)
- Davies J, Read J 2019 — A systematic review into the incidence, severity and duration of antidepressant withdrawal effects (Addictive Behaviors)
- Framer A 2021 — The patient voice: an exploration of the experience of withdrawal from antidepressants (Therapeutic Advances in Psychopharmacology)
Clinical guidelines
Evidence-based deprescribing and prescribing standards.
Deprescribing-specific resources
Clinician-facing references on tapering protocols.
- Deprescribing.org — Evidence-based deprescribing algorithms from the Bruyère Research Institute
- Royal College of Psychiatrists — Stopping antidepressants — UK clinical guidance on safely discontinuing antidepressants
Patient-advocacy & lived-experience
Long-running communities documenting withdrawal experience.
- Surviving Antidepressants — tapering forum — Long-running community archive of antidepressant taper experiences
- Inner Compass Initiative — Withdrawal Project — Peer-led resources for psychiatric drug withdrawal
- Mad in America — antidepressant withdrawal archive — Journalism and personal narratives on SSRI/SNRI discontinuation
- RxISK — adverse drug reaction reporting — Independent database of patient-reported adverse effects
TaperCommunity does not provide medical advice. Always consult a qualified prescriber before adjusting psychiatric medication.